Traws Pharma (TRAW) Competitors $1.60 -0.02 (-1.23%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.61 +0.01 (+0.56%) As of 07/18/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRAW vs. BDRX, SNYR, RNTX, SONN, CLNN, ESLA, SCYX, FGEN, DYAI, and ENLVShould you be buying Traws Pharma stock or one of its competitors? The main competitors of Traws Pharma include Biodexa Pharmaceuticals (BDRX), Synergy CHC (SNYR), Rein Therapeutics (RNTX), Sonnet BioTherapeutics (SONN), Clene (CLNN), Estrella Immunopharma (ESLA), SCYNEXIS (SCYX), FibroGen (FGEN), Dyadic International (DYAI), and Enlivex Therapeutics (ENLV). These companies are all part of the "pharmaceutical products" industry. Traws Pharma vs. Its Competitors Biodexa Pharmaceuticals Synergy CHC Rein Therapeutics Sonnet BioTherapeutics Clene Estrella Immunopharma SCYNEXIS FibroGen Dyadic International Enlivex Therapeutics Biodexa Pharmaceuticals (NASDAQ:BDRX) and Traws Pharma (NASDAQ:TRAW) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings. Which has more risk & volatility, BDRX or TRAW? Biodexa Pharmaceuticals has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, Traws Pharma has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Which has better earnings & valuation, BDRX or TRAW? Biodexa Pharmaceuticals has higher revenue and earnings than Traws Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiodexa Pharmaceuticals$470K65.66-$7.32MN/AN/ATraws Pharma$230K38.68-$166.52M-$32.81-0.05 Is BDRX or TRAW more profitable? Biodexa Pharmaceuticals has a net margin of 0.00% compared to Traws Pharma's net margin of -15,245.81%. Company Net Margins Return on Equity Return on Assets Biodexa PharmaceuticalsN/A N/A N/A Traws Pharma -15,245.81%N/A -193.21% Do institutionals & insiders believe in BDRX or TRAW? 17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. Comparatively, 8.0% of Traws Pharma shares are held by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are held by company insiders. Comparatively, 13.6% of Traws Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media refer more to BDRX or TRAW? In the previous week, Biodexa Pharmaceuticals had 1 more articles in the media than Traws Pharma. MarketBeat recorded 2 mentions for Biodexa Pharmaceuticals and 1 mentions for Traws Pharma. Biodexa Pharmaceuticals' average media sentiment score of 0.00 equaled Traws Pharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biodexa Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Traws Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryBiodexa Pharmaceuticals beats Traws Pharma on 7 of the 9 factors compared between the two stocks. Get Traws Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TRAW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRAW vs. The Competition Export to ExcelMetricTraws PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.01M$2.46B$5.55B$9.41BDividend YieldN/A1.80%3.75%4.03%P/E Ratio-0.058.9428.0119.82Price / Sales38.68709.91432.6698.27Price / CashN/A164.7736.1658.27Price / Book-0.185.008.125.65Net Income-$166.52M$30.99M$3.25B$257.91M7 Day Performance5.26%1.69%1.68%3.38%1 Month Performance-3.03%9.20%7.30%11.11%1 Year PerformanceN/A0.43%32.89%18.99% Traws Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRAWTraws Pharma0.3603 of 5 stars$1.60-1.2%N/AN/A$9.01M$230K-0.0517BDRXBiodexa Pharmaceuticals0.2126 of 5 stars$0.88-10.2%N/AN/A$32.15M$470K0.0020SNYRSynergy CHC3.8211 of 5 stars$3.40+0.3%$10.00+194.1%+3,510.0%$31.25M$34.83M0.0040Positive NewsRNTXRein TherapeuticsN/A$1.40-6.7%N/AN/A$31.01MN/A-0.499SONNSonnet BioTherapeutics3.7814 of 5 stars$9.77+1.3%$20.00+104.7%-10.6%$30.97M$20K0.0010Gap DownHigh Trading VolumeCLNNClene3.0838 of 5 stars$3.70-0.8%$40.00+981.1%-20.4%$30.60M$340K-0.92100Analyst ForecastESLAEstrella Immunopharma3.1694 of 5 stars$0.84-5.5%$16.00+1,813.9%-35.8%$30.24MN/A-3.22N/APositive NewsSCYXSCYNEXIS0.3193 of 5 stars$0.76-7.2%N/A-65.3%$29.66M$2.63M-1.3660FGENFibroGen4.7043 of 5 stars$7.32-4.8%$250.00+3,315.3%-70.6%$29.57M$29.62M-2.93570DYAIDyadic International3.0274 of 5 stars$0.98+1.1%$6.00+512.1%-29.9%$29.50M$3.34M-4.907Positive NewsGap DownENLVEnlivex Therapeutics1.9018 of 5 stars$1.23-3.9%$10.00+713.0%-13.8%$29.09MN/A-1.8670Positive News Related Companies and Tools Related Companies Biodexa Pharmaceuticals Competitors Synergy CHC Competitors Rein Therapeutics Competitors Sonnet BioTherapeutics Competitors Clene Competitors Estrella Immunopharma Competitors SCYNEXIS Competitors FibroGen Competitors Dyadic International Competitors Enlivex Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRAW) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Traws Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Traws Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TRAW Stock Alerts